End-to-end automation of closed manufacturing can make cell therapies more accessible

0


The company hopes to bring personalized and life-saving cell therapy products to market while making them available in a cost-effective and scalable manner. Cellares’ platform, the Cell Shuttle, has a flexible design that can accommodate various cell therapy manufacturing processes that biopharmaceutical companies are already using.

Customers can customize the Cell Shuttle workflow by selecting the specific instrumentation they wish to include for a given cell therapy product. Cellares is also developing software that will allow bioprocessing professionals to customize workflows with a drag-and-drop program to create desired processes.

Gerlinghaus explained how Cellares tackles the two main sources of process failure in the cell therapy industry: contamination and cost. First, Cell Shuttle’s fully closed system mitigates the potential for contamination, which presents a challenge for all cell growth processes. By automating processes, companies can reduce the risk of user error.

Second, Cellares’ automated platform reduces the manpower spent per patient, making it 80% more efficient in terms of cleanroom space compared to current cell manufacturing processes. Gerlinghaus believes that Celleras has the potential to reduce the cost of cell therapy products by up to 75%.

The company’s Cell Shuttle platform can produce both autologous and allogeneic products. The company took into account the different requirements of cell therapy products when designing the Cell Shuttle, such as additional expansion capabilities for allogeneic products, which are derived from healthy donor cells.

The Cellares platform is scalable to accommodate a number of patients on a commercial scale – more than 10,000 patients per year, per drug. This is achieved by the platform’s ability to run 10 process steps simultaneously, Gerlinghaus said, which creates an order of magnitude improvement in instrument throughput compared to current industry standards.

Related reading

Copyright © 2021 scienceboard.net


Leave A Reply

Your email address will not be published.